47 results about "NH lymphoma" patented technology

Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described. In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.

The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.

The invention belongs to the technical field of antibody drugs and provides a completely anti-CD20 human monoclonal antibody and an application thereof. The antibodies come from human hybridomas by virtue of cellular poison functional test screening and CD20 affinity screening, and the antibodies have excellent CD20 affinity and specificity and an obvious cellular poison effect on lymphoma cells; in a pharmacodynamic experiment of a Raji cell infiltrating tumor model for treating human B cell lymphoma, lifetime of an experimental animal is obviously prolonged; in a Raji cell orthotopic transplantation tumor inhibiting experiment for treating human B cell lymphoma, growth of transplant subcutaneous sarcoma of Raji cells is obviously inhibited; curative effect not lower than or better than that of rituximab is respectively shown in lifetime and tumor growth inhibiting; and the completely anti-CD20 human monoclonal antibody has potential diagnosis and treatment values on diseases such as non-hodgkin lymphomas, B cell lymphoma, rheumatic and rheumatoid diseases, systemic lupus erythematosus, immune thrombocytopenic purpura and multiple sclerosis.

The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.

Methods are provided for the treatment of relapsed and / or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).

The invention belongs to the technical field of medicine, particularly relates to a heterocyclic nitrogen compound which acts as a tyrosine kinase inhibitor and is represented by a general formula (I) as well as a deuterated material, pharmaceutically acceptable salt or stereisomer thereof. In the general formula (I), X, W, R1, R2, R3, L1, L2, a, b, c, d, e, p, q, a ring A and a ring B are defined in specification. The invention further relates to a preparation method of the compounds, a pharmaceutic preparation containing the compounds, and important actions of the compounds in treatment of leukemia (such as B cell chronic lymphocytic carcinoma and non-hodgkin lymphoma) related to B cell, and autoimmune diseases (such as rheumatoid arthritis and systemic lupus erythematosus).

The invention belongs to the technical field of medicine, and particularly relates to an injection for treating NHL (non-hodgkin lymphoma) and a preparation method thereof. The injection for treating NHL is mainly prepared from active ingredients of maleic acid pixantrone, sodium chloride, dispersing agents, nzyl benzoate, sodium citrate, pH regulators and injection water. The injection for treating NHL has the advantages that the quality is stable; all indexes conform to the quality requirements; the process is simple; the operation is convenient.

The invention relates to an anti-CD20 monoclonal antibody, a preparation method and an application of the anti-CD20 monoclonal antibody; Chinese hamster ovary cells CHODG44 are adopted to prepare the anti-CD20 monoclonal antibody consistent to rituximab, thereby establishing a large-scale high-expression production technology for 300L of eukaryocytes, wherein the protein expression quantity is more than 1.2g / L and the protein purification yield is improved to more than 60%. The anti-CD20 monoclonal antibody is safe, effective, relatively strong in practicability, low in cost, convenient and quick, and the preparation technology of the anti-CD20 monoclonal antibody is simple and convenient, easy to operate and use and obvious in curative effect, thereby providing a new source of medicines for the B cell induced malignant tumors, particularly the non-hodgkin lymphoma, autoimmune disease, renal failure, hepatitis B, hepatitis C and diabetes, etc.; the anti-CD20 monoclonal antibody is applied to the large-scale production and commercial application in the industries such as medicine, biotechnology and the like and has a good application prospect, remarkable social benefit and economic benefit.